Drew Scientific doubles interim turnover:
This article was originally published in Clinica
Drew Scientific, UK-based manufacturer of diabetic care devices, has more than doubled its interim sales to £1.1 million ($1.7 million) in the six months to September compared with £431,000 in the previous year. The after-tax loss fell to £97,000 from £515,000. CEO Keith Drew says the results are "still unsatisfactory, [but] encouraging". Drew's US distributor, Bio-Rad, launched DiaSTAT in the US and is extending into markets outside the US.